Suit Targets Impax’s Move To Sell Generic Amrix

Law360 (January 8, 2009, 12:00 AM EST) -- Impax Laboratories Inc. said Thursday it has been tied into a patent infringement suit over its plans to market a generic Amrix, a skeletal muscle relaxant produced by Pennsylvania-based Cephalon Inc.

Cephalon lodged the suit in the U.S. District Court for the District of Delaware after the Hayward, Calif.-based specialty pharmaceutical firm submitted an abbreviated new drug application for cyclobenzaprine hydrochloride extended release capsules to the U.S. Food and Drug Administration, according to Impax.

Impax’s ANDA includes a Paragraph IV certification, which asserts the generic version...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.